Galectin-1驱动单核细胞过度炎症并成为骨髓增殖性肿瘤的新治疗靶点
该研究通过单细胞RNA测序发现MPN单核细胞中galectin基因显著富集,并证实Gal-1在患者和小鼠模型单核细胞中表达升高。Gal-1通过TLR4/NF-κB通路促进单核细胞炎症因子转录和分泌,遗传敲除Lgals1可改善MPLW515L小鼠的白细胞增多和脾肿大,提示Gal-1是MPN的潜在治疗靶点。
要点
- MPN单核细胞中galectin基因富集且Gal-1表达升高。
- Gal-1经TLR4/NF-κB促进单核细胞炎症因子产生。
- 敲除Lgals1改善MPLW515L小鼠的白细胞增多和脾肿大。
核心结论
- Gal-1在MPN单核细胞中富集,通过TLR4和NF-κB激活驱动单核细胞介导的炎症,是MPN的新治疗靶点。
研究设计与样本
- 研究采用单细胞RNA测序、质谱流式、共免疫沉淀和报告基因实验,并在MPLW515L小鼠模型中进行体内验证。
主要发现
- 单细胞RNA测序显示MPN单核细胞中galectin基因显著富集,细胞通讯分析预测单核细胞为关键介导者且galectin信号为单核细胞的输入/输出通路。
- 质谱流式显示重组Gal-1显著增加MPN血液样本中单核细胞的多种炎症因子水平,而不影响其他细胞类型。
- MPN患者CD14+单核细胞与rGal-1孵育后炎症因子的转录和分泌显著增加。
- TLR4抑制可消除Gal-1介导的单核细胞促炎效应,报告基因实验显示rGal-1以TLR4依赖方式激活NF-κB信号。
- 在MPLW515L小鼠模型中,遗传敲除Lgals1改善了白细胞增多和脾肿大等关键MPN疾病特征,Gal-1抑制还抑制了角叉菜胶诱导的血栓形成和炎症。
临床怎么用
- Gal-1及其下游TLR4/NF-κB通路可作为MPN炎症驱动的治疗靶点,需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dysregulation of galectins and global protein glycosylation has been reported in various cancers, but their role in myeloproliferative neoplasms (MPNs) remains incompletely understood. We performed single-cell RNA sequencing, which revealed significant enrichment of galectin genes in MPN monocytes. Cell-cell communication analysis predicted monocytes as a pivotal mediator of intercellular interactions and galectin signaling as a robust input/output pathway in monocytes. We identified elevated expression of galectin-1 (Gal-1, LGALS1) in monocytes from both human MPN samples and mouse models. Mass cytometry profiling of MPN blood samples demonstrated that recombinant Gal-1 (rGal-1) significantly increased levels of multiple inflammatory cytokines in monocytes without affecting other cell types. Incubation of CD14+ monocytes from patients with MPN with rGal-1 markedly increased the transcription and secretion of inflammatory cytokines. Mechanistically, we uncovered cross talk between the toll-like receptor 4 (TLR4) and Gal-1 signaling pathways, as evidenced by protein 3-dimensional modeling and coimmunoprecipitation analyses. Notably, TLR4 inhibition abrogated the Gal-1-mediated proinflammatory effects in monocytes. We further identified NF-κB-dependent signaling as a key downstream effector of Gal-1, as reporter assays demonstrated rGal-1-mediated activation of NF-κB signaling in a TLR4-dependent manner. We corroborated these findings in vivo in a murine model driven by MPLW515L, in which genetic abrogation of Lgals1 ameliorated key MPN disease features, including leukocytosis and splenomegaly. In addition, Gal-1 inhibition suppressed carrageenan-induced thrombosis and inflammation in vivo. In summary, we identify Gal-1 enrichment in MPN monocytes as a driver of monocyte-mediated inflammation through TLR4 and NF-κB activation and uncover a novel therapeutic avenue for MPNs.
引用
- He F, Lin S, Kong T, et al. Galectin-1 fuels monocyte hyperinflammation and is a novel therapeutic target in myeloproliferative neoplasms. Blood. 2026. PMID: 42345360. doi:10.1182/blood.2025032631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。